Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Bedrock Therapeutics Inc
Profile last edited on: 2/17/2023      CAGE: 82SX8      UEI: SB2ZXJBQ4SX3

Business Identifier: AAV R&D gene therapy
Year Founded
2018
First Award
2020
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

8628 Valley Brook Drive
Chapel Hill, NC 27613
Location: Single
Congr. District: 02
County: Orange

Public Profile

Bedrock Therapeutics is an AAV research and development company working both on platform technologies and therapeutic cassettes for diverse genetic diseases. The firm is structured around development of a method to improve the success of human corneal transplants by controlling the human bodyÂ’s immune response and reduce transplant rejection

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$916,617
Phase II Dollars
$171,923
Total Awarded
$1,088,540

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $261,080
Project Title: Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion
2021 1 NIH $328,150
Project Title: Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease
2021 1 NIH $250,000
Project Title: Prevention of Corneal Transplant Rejection Using Aav-Hla-G Combination Therapy
2020 1 NIH $249,310
Project Title: Develop Humanized AAV Vectors for Liver Targeting and Neutralizing Antibody Evasion

Key People / Management

  Matthew Hirsch -- President and Co-Founder, Director of AAV Ocular Therapy

  Brian C Gilger -- Co-Founder, Director of Preclinical Evaluation and Toxicology

  Sun Junjet Al

  Chengwen Li

  Fran Martin -- Vice President, Commercial Development and Consulting

  Junjiang Sun

  Roger “bryan” Sutton

Company News

There are no news available.